Skip to content

Development of Biomarkers Associated with Secondary Infections and Multi-Organ Injury in Sepsis Patients' Peripheral Blood Using Multi-Omics Approaches: An Evidence-Based Medical Research

Development of Biomarkers Associated with Secondary Infections and Multi-Organ Injury in Sepsis Patients' Peripheral Blood Using Multi-Omics Approaches: An Evidence-Based Medical Research

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121437
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Observation group (Patients with sepsis, including septic shock):None
Control group:None

Sponsors

Baotou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Meet the diagnostic criteria for sepsis as defined in the "International Consensus on the Third Edition of Sepsis and Septic Shock" (Sepsis-3), that is, after a clear or highly suspected infection, the Sequential Organ Failure Assessment (SOFA) score increases by = 2 points compared to the baseline; 3. Patients who is hospitalized in the intensive care unit (ICU) or a related critical care ward, and has received standardized comprehensive treatment in accordance with the current guidelines for sepsis management; 4. With complete clinical data and follow-up information, it is possible to assess whether secondary infections occurred during hospitalization and within 28 days, as well as related clinical outcomes. 5. The subjects themselves or their legal representatives signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years old; 2. Patients with clearly identified severe underlying diseases that may significantly affect immune status or survival prognosis, such as advanced malignant tumors, end-stage liver disease or end-stage kidney disease; 3. Patients with clearly diagnosed hematological diseases or autoimmune disorders; 4. Patients who have been receiving immunosuppressive therapy for a long time (such as long-term high-dose glucocorticoids or immunosuppressants); 5. Patients who cannot obtain complete clinical data or cannot complete the collection of research-related samples.

Design outcomes

Primary

MeasureTime frame
Bulk RNA-seq of PBMC;Single-cell RNA-seq of PBMC;Landscape of plasma lncRNA;Proteome of plasma;

Countries

China

Contacts

Public ContactXu Teng

Baotou Central Hospital

568185901@qq.com+86 186 8618 8554

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026